Gordon, Familant Join Baker Botts as Part of Expanded Life Sciences IP ... ( Partners' Careers Focus on Biotech Ph...)

Gordon, Familant Join Baker Botts as Part of Expanded Life Sciences IP Initiative

Date:1/12/2009

Partners' Careers Focus on Biotech, Pharmaceutical Patents

NEW YORK, Jan. 12 /PRNewswire/ -- Jennifer Gordon and Scott Familant, who have extensive experience in complex patent matters in the life sciences, joined Baker Botts L.L.P. January 5, 2009, as partners in the Intellectual Property Department. Gordon will head up the IP Department's Life Sciences section. Both lawyers will be based in the firm's New York City office.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090112/DA57603-a)

(Photo: http://www.newscom.com/cgi-bin/prnh/20090112/DA57603-b)

Throughout their careers, Gordon and Familant have procured, litigated and provided counsel on patents involving virtually all aspects of biotechnology, most notably litigating foundational patents in the areas of nucleic acid amplification and recombinant antibody production. Their pharmaceutical patent experience encompasses a broad spectrum, from the earliest therapeutic proteins and monoclonal antibodies to recent blockbuster drugs for lowering cholesterol and treating type II diabetes.

"Jennifer and Scott joining Baker Botts at this time demonstrates our commitment to recruiting highly-skilled individuals with extensive experience in areas where our clients are increasingly looking to us for counsel," said Baker Botts Managing Partner Walt Smith. "With a focus on life science matters, the addition of Jennifer and Scott to our talented team of IP lawyers increases our depth of knowledge and legal expertise in the intellectual property arena."

Commenting on the move to Baker Botts, Gordon said: "Baker Botts' strategic focus on the life sciences and its exceptional full service intellectual property practice were very attractive to Scott and me. W
'/>"/>

SOURCE Baker Botts L.L.P.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
2. Isabellas Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic
3. VivoMetrics(R) Appoints Howard R. Baker as New President and Chief Executive Officer
4. Align Technology Receives Expanded Regulatory Approval in Japan
5. Biotech Endorsement Insurance Discount Expanded to Nebraska, Kansas Growers Planting Corn with HERCULEX XTRA Traits
6. Backe Digital-Brand-Marketing Blends Traditional Advertising with Expanded Digital Services
7. ACIST Medical Systems Announces the Opening of Its New Expanded Corporate Headquarters in Eden Prairie, MN
8. Codexis, Arch Announce Expanded Collaboration
9. Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June
10. Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test
11. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... with financial software provider BlackLine Systems and enterprise ... SAP ) for a webinar next week entitled "No ... from BlackLine and SAP to Help Keep Its Account Reconciliations ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at finance, ...

(Date:6/19/2013)... (PRWEB) June 18, 2013 A new ... materials, costs and other trends will highlight technical sessions ... California this fall. In its 33rd year, the three-day ... an exhibition of key suppliers, approximately 100 technical presentations ... SPIE, the international society for optics and photonics , ...

(Date:6/18/2013)... KONG, June 18, 2013 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2013 ended March 31, 2013. Fourth ... the fourth quarter of fiscal 2013 increased by 33.3% ...

(Date:6/18/2013)... 18, 2013 The human skin is the ... an important human body part. Similar to the liver, or ... to function, repair and grow. Recent reports from the mankatofreepress.com ... is just as important as other life supporting organs. The ... in skin cell reproduction, increase the appearance of skin, and ...

[0] Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations [0] ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin

... Halozyme Therapeutics, Inc. (Nasdaq: HALO ) ... the first patient received subcutaneous (SC) MabThera (rituximab), an ... Enhanze(™ technology (rHuPH20, recombinant human hyaluronidase). This ... Herceptin ® SC (trastuzumab), to enter a Phase ...

... Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... officer, will deliver the Company,s corporate presentation at Lippert/Heilshorn ... on Thursday, February 17, 2011 at 11:30 a.m. Eastern ... webcast with slide presentation at: www.transgenomic.com , or ...

... ROCKVILLE, Md., Feb. 15, 2011 Neuralstem, Inc. (NYSE ... business leader Stanley I. Westreich to its Board of ... comprised of a majority of independent directors. ... of Neuralstem,s Board of Directors and the Company,s Chief ...

Cached Biology Technology:Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 2 Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 3 Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 4 Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 2 Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 3 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 2 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 3

Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board

(Date:6/19/2013)... of mammals and birds are threatened with extinction as a ... and colleagues from The Ohio State University in the US. ... exponential growth of the human population will continue to pose ... not appear to be a threshold above which population growth ... is published online in Springer,s journal, Human Ecology . ...

(Date:6/19/2013)... New York, NY, June 19, 2013 A ... Diabetes Research in Helmholtz Zentrum Mnchen, Germany, is ... autoantibodies and the risk of developing type 1 ... into possible preventions for the disease. The study, ... Progression to Diabetes in Children," was published today ...

(Date:6/19/2013)... offers further proof that the divergence of humans from ... was profoundly influenced by mutations to DNA sequences that ... The study, published June 9 in Nature Genetics ... of genes must play an important role in evolution ... in the proteins produced by genes. Indeed, human and ...

Breaking Biology News(10 mins):Are we pushing animals over the edge? 2 New data on islet autoantibodies in young children defines early type 1 diabetes development 2 New research backs theory that genetic 'switches' play big role in human evolution 2 New research backs theory that genetic 'switches' play big role in human evolution 3

[0] Are we pushing animals over the edge?[0] New data on islet autoantibodies in young children defines early type 1 diabetes development [0] New research backs theory that genetic 'switches' play big role in human evolution

... Bette Korber is part of an international team of ... trial of a mosaic HIV vaccine candidate. The vaccine ... causes AIDS by attempting to address one of the ... extensive genetic diversity. The team and its efforts ...

... UPTON, NY Scientists at the U.S. Department of ... have discovered a key difference in the way human ... unwanted proteins marked with a "kiss of death" ... critical difference, described in a paper published online October ...

... TAMPA, Fla., Sept. 22 Lockheed Martin (NYSE: ... new DNA analysis system that has potential to transform how ... in support of their missions. The prototype, called ... Biometric Consortium Conference special session on Rapid DNA. The ...

Cached Biology News:Consortium to design human trials of mosaic HIV vaccine 2 Key difference in how TB bacteria degrade doomed proteins 2 Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2 Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3

Consortium to design human trials of mosaic HIV vaccine Key difference in how TB bacteria degrade doomed proteins Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities

... no longer need to perform time consuming and ... Mutation Surveyor, any found variants of the sample ... indicated in our mutation electropherogram as a sharp ... bi-directional analysis mode is over 99%, with sensitivity ...

...

... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...

Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...

Biology Products:

Mutation Surveyor from SoftGenetics, LLC.Finnigan LTQ FT from Thermo Scientific Helios Gene Gun System, 220-240 V from Bio-Rad Mouse Anti-Human YARS Monoclonal Antibody, Unconjugated, Clone 2F3 from Abnova Corporation